Which major peptide vendors shut down in 2025–2026?

Peptide Sciences (March 6, 2026, voluntary), Science.bio (January 2026, voluntary), Paradigm Peptides (December 2025, after the founders' guilty pleas), and Amino Asylum (reported offline around June 2025). Trade reporting indicates at least seven additional vendors closed during 2025.

Did the FDA shut down Peptide Sciences?

No official FDA closure order was reported. The company described its March 6, 2026 closure as voluntary and permanent. It closed amid an escalating enforcement and litigation environment rather than under a specific published FDA shutdown order.

Is it still possible to buy research peptides in 2026?

Yes — several research-use-only suppliers continue to operate. The evaluation checklist above (lot-matched documentation, RUO labeling, domain age, transparent entity, payment) is how to vet the ones that remain. Material is supplied for laboratory research, not human use.

Does the April 2026 Category-2 change make these peptides legal?

No. Removing peptides from the Category 2 list is a compounding-pathway procedural step; it is not FDA approval and does not authorize human use. Research-use-only materials are a separate lane from compounded human-use products.

What is Titan Peptide Lab?

A research-use-only peptide supplier that operates crypto-only and provides lot-matched release documentation on request. Products are for laboratory and research use only, not for human consumption, diagnosis, or treatment.

Vendor shutdown timeline · 2025–2026 · research use

Peptide Vendors That Shut Down in 2025–2026: The Full Timeline (and Who's Still Operating)

If a research supplier you used has gone offline, you're not imagining a trend — the research-peptide market contracted sharply across 2025 and early 2026. Several of the largest names in the space closed within roughly a year of each other, some voluntarily and some under legal pressure. This page is a plain, dated, sourced record of what happened, followed by how to sanity-check any vendor that's still shipping. Dates reflect the best available public reporting as of mid-2026; where an event is community-reported rather than confirmed in official records, it's marked as such. This is general market and regulatory context only — not legal advice, not medical advice, and not a statement about using any substance in humans. Titan Peptide Lab supplies materials for laboratory and research use only (RUO).

How to evaluate a vendor still operating Peptide Sciences alternative — the vetting rubric

Why so many closed at once

Three overlapping pressures converged. First, escalating FDA warning-letter enforcement — more than 50 letters had gone out by September 2025. Second, pharmaceutical litigation from Eli Lilly and Novo Nordisk over tirzepatide and semaglutide, which pulled compounders and distributors into court. Third, and most consequential, the shift from civil warnings to criminal prosecution: the Paradigm Peptides guilty pleas in December 2025 meant principals faced personal exposure, not just business fines. Against that backdrop, the larger voluntary exits — Peptide Sciences and Science.bio — read as calculated departures ahead of enforcement rather than failing businesses.

Vetting after the shutdowns →

Category-2 reclassification is a separate thread

In April 2026 the FDA also removed twelve peptides — including BPC-157 and TB-500 — from its Category 2 compounding list, and scheduled a July 23–24 advisory meeting. It's easy to fold that into the shutdown story, but it's a different question: coming off Category 2 is a compounding-pathway procedural step, not FDA approval, and it does not legalize human use of anything. It concerns human-use pharmacy preparation, a lane separate from research-use-only material.

BPC-157 legal status, explained →

How to evaluate a vendor that's still operating

A short, neutral checklist — useful for judging any supplier, including Titan. 1) Batch/lot-matched documentation: does the vendor tie test results to the specific lot you'd receive, not a generic marketing PDF? 2) Research-use-only labeling with no therapeutic claims — vendors making human dosing or efficacy claims are the ones drawing enforcement. 3) Domain age and community history: multiple lookalike sites launched within days of the Peptide Sciences closure, so check registration date and prior presence. 4) A transparent contact path and real entity, not email-only anonymity. 5) Payment-method reality — understand the tradeoffs of each rail; crypto settlement became common in this space post-consolidation.

Current-lot documentation checklist →

Watch for lookalike domains

One durable side effect of a large closure is impersonation. After Peptide Sciences went offline, new storefronts appeared quickly, some deliberately echoing closed brands to capture their search traffic. A brand-new site with no operating history is a different risk profile than an established operation, regardless of how polished it looks. Domain age plus lot paperwork plus honest labeling is what separates a considered choice from a gamble — and no ranking or 'best of' list can verify those for you.

How to check a vendor's history →

Where Titan fits (honestly)

Titan Peptide Lab is one of the research-use-only suppliers still operating after the consolidation. Titan is crypto-only, labels everything for research use only, and provides lot-matched release documentation on request rather than a generic marketing sheet. Titan is not going to tell you it's the 'best' or '#1' vendor — the checklist above exists so you can judge any supplier, including Titan, on the same terms. Compounds referenced here are supplied strictly for laboratory research, not for human use.

The honest ranking rubric →

The shutdown timeline · 2024–2026

What closed, when, and why — a dated, sourced record.

Where an event is community-reported rather than confirmed in official FDA or DOJ records, it's marked as reported. Trade reporting indicates at least seven additional research-peptide companies closed during 2025 beyond those named here; exact headcounts vary by source. None of the below is a statement about human use of any compound.

Dec 2024: FDA warning letters to Prime Peptides, Xcel Peptides, SwissChems and Summit Research — the first coordinated enforcement wave.
May 2024: Eli Lilly's ITC tirzepatide complaint names Strate Labs, which is found in default and issued a cease-and-desist.
Apr 2025: Eli Lilly sues telehealth companies over tirzepatide — establishing pharma-litigation precedent.
~Jun 2025: Amino Asylum goes offline. Widely described in the community as an FDA warehouse raid, but that raid is reported, not confirmed in public FDA/DOJ records.
Aug 2025: Novo Nordisk sues 14 semaglutide distributors, broadening the litigation beyond tirzepatide.
Sep 2025: More than 50 FDA warning letters issued — a mass enforcement wave across GLP-1 compounders and vendors.
Dec 10, 2025: Paradigm Peptides founders plead guilty (products labeled as SARMs contained testosterone, plus unapproved-drug charges). The site now shows a closure notice.
Jan 2026: Science.bio permanently closes — a voluntary exit by a long-respected vendor.
Feb 27, 2026: HHS Secretary RFK Jr. publicly addresses the Category 2 peptides ahead of the reclassification.
Mar 6, 2026: Peptide Sciences — the industry's largest vendor, with an estimated ~$7.4M/month in online sales as of Dec 2025 — announces a voluntary, permanent shutdown; the site goes offline.
Apr 15–16, 2026: FDA removes 12 peptides from Category 2 via Federal Register notice, after original nominations were withdrawn. This is not FDA approval.
Jul 23–24, 2026: PCAC reviews 503A eligibility (Jul 23: BPC-157, KPV, TB-500, MOTS-C; Jul 24: DSIP, Semax, Epitalon). Recommendations are non-binding.
Ongoing 2026: The SAFE Drugs Act is introduced, which would bar sale of research chemicals identical to FDA-approved drugs without a new drug application.

Questions researchers ask

Before you order.

Which major peptide vendors shut down in 2025–2026?: Peptide Sciences (March 6, 2026, voluntary), Science.bio (January 2026, voluntary), Paradigm Peptides (December 2025, after the founders' guilty pleas), and Amino Asylum (reported offline around June 2025). Trade reporting indicates at least seven additional vendors closed during 2025.
Did the FDA shut down Peptide Sciences?: No official FDA closure order was reported. The company described its March 6, 2026 closure as voluntary and permanent. It closed amid an escalating enforcement and litigation environment rather than under a specific published FDA shutdown order.
Is it still possible to buy research peptides in 2026?: Yes — several research-use-only suppliers continue to operate. The evaluation checklist above (lot-matched documentation, RUO labeling, domain age, transparent entity, payment) is how to vet the ones that remain. Material is supplied for laboratory research, not human use.
Does the April 2026 Category-2 change make these peptides legal?: No. Removing peptides from the Category 2 list is a compounding-pathway procedural step; it is not FDA approval and does not authorize human use. Research-use-only materials are a separate lane from compounded human-use products.
What is Titan Peptide Lab?: A research-use-only peptide supplier that operates crypto-only and provides lot-matched release documentation on request. Products are for laboratory and research use only, not for human consumption, diagnosis, or treatment.